PDS Biotechnology announces data on activity of PDS0101, PDS01ADC

PDS Biotechnology (PDSB) announced positive clinical and translational data presented at the 2025 Society for Immunotherapy of Cancer, SITC, Annual Meeting. The presentations highlight immune-driven mechanisms and biomarkers that explain strong clinical activity of the Company’s investigational HPV16-targeted immunotherapy PDS0101 and its novel, investigational immunocytokine PDS01ADC. The studies were performed as part of PDS Biotech’s collaborative research and development agreement, CRADA, with the National Cancer Institute, NCI, Center for Cancer Research, CCR. Presentations at SITC 2025 included one rapid oral abstract, recognized among the top 150 abstracts of the meeting, and two poster presentations.